Literature DB >> 22380008

Aptamers as remarkable diagnostic and therapeutic agents in cancer treatment.

Henri-Pierre Lassalle1, Sophie Marchal, François Guillemin, Aurélie Reinhard, Lina Bezdetnaya.   

Abstract

Nucleic acid aptamers are molecules that are being used in a large number of biomedical applications. Aptamers have the properties to bind to a wide range of molecules with high specificity and affinity for their target. These properties together with their small size and their ease of synthesis make them very attractive and promising for targeting diseases and therapeutic applications. Aptamers can serve as cancer diagnostic tools by detecting specific biomarkers, circulating cancer cells or imaging diseased tissue. On the other hand, aptamers can be used as therapeutic agents due to their potential antagonist activity, or as targeting agents. Therefore, they can be designed to deliver antitumor molecules such as chemotherapeutic drugs, siRNA or photodynamic therapy sensitizers to diseased tissues. Attempts are also made to synthesize aptamers-targeted nanoplatforms capable to ferry cargo and load onto them both imaging and therapeutic functions creating so called nanotheragnostics agents. In the future, its seems likely that aptamers will play an important role in diagnosis and treatment of several pathologies including cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22380008     DOI: 10.2174/138920012802850038

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  7 in total

1.  Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia.

Authors:  Nianxi Zhao; Sung-Nan Pei; Jianjun Qi; Zihua Zeng; Swaminathan P Iyer; Pei Lin; Ching-Hsuan Tung; Youli Zu
Journal:  Biomaterials       Date:  2015-07-15       Impact factor: 12.479

2.  In vivo SELEX for Identification of Brain-penetrating Aptamers.

Authors:  Congsheng Cheng; Yong Hong Chen; Kim A Lennox; Mark A Behlke; Beverly L Davidson
Journal:  Mol Ther Nucleic Acids       Date:  2013-01-08       Impact factor: 10.183

3.  Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome.

Authors:  Shuai Zhen; Yoichiro Takahashi; Shunichi Narita; Yi-Chen Yang; Xu Li
Journal:  Oncotarget       Date:  2017-02-07

4.  How fibrosis influences imaging and surgical decisions in pancreatic cancer.

Authors:  Mert Erkan; Simone Hausmann; Christoph W Michalski; Anna M Schlitter; Alexander A Fingerle; Martin Dobritz; Helmut Friess; Jörg Kleeff
Journal:  Front Physiol       Date:  2012-10-02       Impact factor: 4.566

5.  The use of sensitive chemical antibodies for diagnosis: detection of low levels of EpCAM in breast cancer.

Authors:  Sarah Shigdar; Christine Qian; Li Lv; Chunwen Pu; Yong Li; Lianhong Li; Manju Marappan; Jia Lin; Lifen Wang; Wei Duan
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

6.  A DNA aptamer with high affinity and specificity for molecular recognition and targeting therapy of gastric cancer.

Authors:  Hong-Yong Cao; Ai-Hua Yuan; Wei Chen; Xue-Song Shi; Yi Miao
Journal:  BMC Cancer       Date:  2014-09-23       Impact factor: 4.430

Review 7.  Fluorescent Sensors for the Detection of Heavy Metal Ions in Aqueous Media.

Authors:  Nerea De Acha; César Elosúa; Jesús M Corres; Francisco J Arregui
Journal:  Sensors (Basel)       Date:  2019-01-31       Impact factor: 3.576

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.